

Report from the 2022 International PDPN Meeting

Rachel E. Nicoletto (Rowan University)

The third International Podoplanin (PDPN) Meeting was held on December 8, 2022 at the Alexandrian Hotel in Oldtown Alexandria, VA, USA. The meeting followed the ASCB/EMBO joint meeting held from December 3 – 7, 2022 in Washington, DC. The meeting provided a venue to understand the diverse roles of PDPN and advance scientific exploration in the field. The meeting featured presentations by Amanda A. Greenspan (Rowan University), Antonia Wallrapp (Harvard University), Christian Naus (University of British Columbia), Eamonn J. Brace (Rowan University), Gary S. Goldberg (Rowan University), Harini Krishnan (Stony Brook University), Julie Rayes (University of Birmingham), Atsushi Natsume (Nagoya University), Maria Cimini (Temple University), Steve Watson (University of Birmingham), Jian-Guo Geng (University of Michigan), Aki Furusawa (National Institutes of Health), and Randy Stout (New York Institute of Technology). These presentations focused on the inflammatory role of PDPN in rheumatoid arthritis, airway inflammation, ischemic injury, infection, and thrombosis. Effects of PDPN targeting in cancers such as human oral squamous cell carcinoma and glioblastoma were also discussed. Taken together, data indicate that PDPN and CLEC-2 interactions regulate immune cell recruitment during inflammation, PDPN signaling promotes inflammation and macrophage recruitment, oncogenic tyrosine kinase induces PDPN expression to promote tumor progression which can be reduced by cadherin mediated communication with nontransformed cells, knowledge of PDPN mutations might provide valuable information to guide investigations of PDPN mutations in cancers, and PDPN can be targeted by biological agents to decrease arthritic inflammation and cancer progression. The next International PDPN meeting is being planned for 2025.